{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:48:35Z","timestamp":1786661315013,"version":"build-2736575974"},"reference-count":176,"publisher":"Elsevier","isbn-type":[{"value":"9780443432361","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019077","name":"Mount Sinai Children's Center Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031162","name":"Sanford Burnham Prebys","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA280194"],"award-info":[{"award-number":["R01 CA280194"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA244993"],"award-info":[{"award-number":["R01 CA244993"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA259599"],"award-info":[{"award-number":["R01 CA259599"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA275740"],"award-info":[{"award-number":["P01 CA275740"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013759","name":"Commonwealth Health Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013759","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016350","name":"Massey Comprehensive Cancer Center, Virginia Commonwealth University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.acr.2026.02.007","type":"book-chapter","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:52:01Z","timestamp":1778723521000},"page":"321-374","source":"Crossref","is-referenced-by-count":1,"title":["Cancer terminator viruses: Unique conditionally replication competent oncolytic viruses producing therapeutic anti-cancer immunomodulating agents"],"prefix":"10.1016","author":[{"given":"Pritam Kumar","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid Maqbool","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsimha","family":"Mamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanabhan","family":"Mannangatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Gammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"David D","family":"Limbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanand","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swadesh K","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/v17010016","article-title":"Employing the oncolytic vesicular stomatitis virus in cancer virotherapy: Resistance and clinical considerations","volume":"17","author":"Abdelmageed","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41389-017-0020-8","article-title":"Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad\u2206\u2206 through Bcl-2-dependent attenuation of autophagy","volume":"7","author":"Aguirre-Hern\u00e1ndez","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/bs.acr.2026.02.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103980","article-title":"Nano based-oncolytic viruses for cancer therapy","volume":"185","author":"Ajam-Hosseini","year":"2023","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0004","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/77283","article-title":"Replicative adenoviruses for cancer therapy","volume":"18","author":"Alemany","year":"2000","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0005","article-title":"The dual promise of oncolytic viruses: Selective targeting and therapeutic enhancement in cancer treatment","volume":"5","author":"Aljabali","year":"2025","journal-title":"Open Exploration"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0006","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cancers17050880","article-title":"Revolutionary cancer therapy for personalization and improved efficacy: Strategies to overcome resistance to immune checkpoint inhibitor therapy","volume":"17","author":"Almawash","year":"2025","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/bs.acr.2026.02.007_bib0007","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.70445\/gjabs.1.1.2024.22-52","article-title":"Combat between oncolytic vesicular stomatitis virus and cancer cells","volume":"1","author":"Atique","year":"2024","journal-title":"Global Journal of Agricultural and Biological Sciences"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0009","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/jcp.22947","article-title":"Enhanced delivery of Mda-7\/IL-24 using a serotype chimeric adenovirus (Ad.5\/3) in combination with the apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells","volume":"227","author":"Azab","year":"2012","journal-title":"Journal of Cellular Physiology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0010","first-page":"34","article-title":"Enhanced prostate cancer gene transfer and therapy using a novel serotype chimera cancer terminator virus (Ad.5\/3-CTV)","volume":"229","author":"Azab","year":"2014","journal-title":"Journal of Cellular Physiology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0011","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1038\/s41467-023-38651-x","article-title":"Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies","volume":"14","author":"Azad","year":"2023","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib179","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and Radiation Therapy: Current Advances and Future Directions","volume":"9","author":"Baskar","year":"2012","journal-title":"International Journal of Medical Sciences"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.007_bib0012","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discovery"},{"issue":"Suppl","key":"10.1016\/bs.acr.2026.02.007_bib0013","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/infdis\/170.Supplement_1.S15","article-title":"Virology of measles virus","volume":"170","author":"Bellini","year":"1994","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0014","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nm.2269","article-title":"Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression","volume":"17","author":"Bhang","year":"2011","journal-title":"Nature Medicine"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.007_bib0015","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1158\/0008-5472.CAN-15-2959","article-title":"Mda-7\/IL-24 induces cell death in neuroblastoma through a novel mechanism involving AIF and ATM","volume":"76","author":"Bhoopathi","year":"2016","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31302","article-title":"Noninvasive therapy of brain cancer using a unique systemic delivery methodology with a cancer terminator virus","volume":"239","author":"Bhoopathi","year":"2024","journal-title":"Journal of Cellular Physiology"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.007_bib0017","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/cancers13040857","article-title":"Theranostic tripartite cancer terminator virus for cancer therapy and imaging","volume":"13","author":"Bhoopathi","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.007_bib0018","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/0008-5472.CAN-09-3647","article-title":"Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7\/interleukin-24","volume":"70","author":"Bhutia","year":"2010","journal-title":"Cancer Research"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0019","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/v15020358","article-title":"A renaissance for oncolytic adenoviruses?","volume":"15","author":"Blanchette","year":"2023","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/156652308784746459","article-title":"Measles virus as an oncolytic vector platform","volume":"8","author":"Blechacz","year":"2008","journal-title":"Current Gene Therapy"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jcp.21320","article-title":"Progression elevated gene-3 promoter (PEG-Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (HPNPase(Old-35))-mediated growth suppression","volume":"215","author":"Chan","year":"2008","journal-title":"Journal of Cellular Physiology"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.007_bib0022","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40259-025-00743-z","article-title":"Oncolytic virotherapy in solid tumors: A current review","volume":"39","author":"Chen","year":"2025","journal-title":"Biodrugs"},{"key":"10.1016\/bs.acr.2026.02.007_bib0023","article-title":"Synergy of oncolytic adenovirus and immune checkpoint inhibitors: Transforming cancer immunotherapy paradigms","volume":"16","author":"Cheng","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.007_bib0024","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14712598.2020.1729351","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors","volume":"20","author":"Chiu","year":"2020","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"16","key":"10.1016\/bs.acr.2026.02.007_bib0025","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-0349-03","article-title":"Use of replicating oncolytic adenoviruses in combination therapy for cancer","volume":"10","author":"Chu","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0026","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ymthe.2004.09.019","article-title":"Clinical and local biological effects of an intratumoral injection of Mda-7 (IL24; INGN 241) in patients with advanced carcinoma: A phase I study","volume":"11","author":"Cunningham","year":"2005","journal-title":"Molecular Therapy : The Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0027","first-page":"1","article-title":"Applications of viruses for cancer therapy","volume":"115","author":"Curiel","year":"2012","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/bs.acr.2026.02.007_bib0028","first-page":"8519","article-title":"Combined UTMD-nanoplatform for the effective delivery of drugs to treat renal cell carcinoma","volume":"19","author":"Dai","year":"2024","journal-title":"International Journal of Nanomedicine"},{"key":"10.1016\/bs.acr.2026.02.007_bib0029","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.matcom.2021.12.004","article-title":"Combination of virotherapy and chemotherapy with optimal control for combating cancer","volume":"194","author":"Das","year":"2022","journal-title":"Mathematics and Computers in Simulation"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14728222.2025.2472042","article-title":"MDA-9\/Syntenin as a therapeutic cancer metastasis target: Current molecular and preclinical understanding","volume":"29","author":"Das","year":"2025","journal-title":"Expert Opinion Therapeutic Targets"},{"key":"10.1016\/bs.acr.2026.02.007_bib0031","first-page":"1","article-title":"Cancer terminator viruses and approaches for enhancing therapeutic outcomes","volume":"115","author":"Das","year":"2012","journal-title":"Advances in Cancer Research"},{"issue":"56","key":"10.1016\/bs.acr.2026.02.007_bib0032","first-page":"46","article-title":"Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic","volume":"11","author":"Dash","year":"2011","journal-title":"Discovery Medicine"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0033","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/0008-5472.CAN-13-1062","article-title":"Novel mechanism of MDA-7\/IL-24 cancer-specific apoptosis through SARI induction","volume":"74","author":"Dash","year":"2014","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0034","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cytogfr.2010.08.004","article-title":"Mda-7\/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity","volume":"21","author":"Dash","year":"2010","journal-title":"Cytokine and Growth Factor Reviews"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cgt.2009.91","article-title":"Enhanced delivery of Mda-7\/IL-24 using a serotype chimeric adenovirus (Ad.5\/3) improves therapeutic efficacy in low CAR prostate cancer cells","volume":"17","author":"Dash","year":"2010","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0036","article-title":"Advances in preclinical and clinical studies of oncolytic virus combination therapy","volume":"15","author":"Du","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0037","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.167.7.3545","article-title":"Cutting edge: STAT activation by IL-19, IL-20 and Mda-7 through IL-20 receptor complexes of two types","volume":"167","author":"Dumoutier","year":"2001","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0038","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ijc.1437","article-title":"Down-regulated melanoma differentiation associated gene (Mda-7) expression in human melanomas","volume":"94","author":"Ekmekcioglu","year":"2001","journal-title":"International Journal of Cancer"},{"key":"10.1016\/bs.acr.2026.02.007_bib0039","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semcancer.2019.07.013","article-title":"Recent insights into apoptosis and toxic autophagy: The roles of MDA-7\/IL-24, a multidimensional anti-cancer therapeutic","volume":"66","author":"Emdad","year":"2020","journal-title":"Seminars in Cancer Biology"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0040","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1002\/jcp.26421","article-title":"Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer","volume":"233","author":"Emdad","year":"2018","journal-title":"Journal of Cellular Physiology"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0041","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4161\/cbt.8.5.7581","article-title":"Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of Mda-7\/IL-24","volume":"8","author":"Emdad","year":"2009","journal-title":"Cancer Biology \\& Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0042","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jcp.20663","article-title":"Ionizing radiation enhances adenoviral vector expressing mda-7\/IL-24-mediated apoptosis in human ovarian cancer","volume":"208","author":"Emdad","year":"2006","journal-title":"Journal Cellular Physiology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0043","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jcp.20097","article-title":"Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: Modulation of genomic stability and invasion","volume":"202","author":"Emdad","year":"2005","journal-title":"Journal of Cellular Physiology"},{"issue":"22","key":"10.1016\/bs.acr.2026.02.007_bib0044","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.1158\/0008-5472.CAN-05-3127","article-title":"Is Mda-7\/IL-24 a \u2018magic bullet\u2019 for cancer?","volume":"65","author":"Fisher","year":"2005","journal-title":"Cancer Research"},{"issue":"4 Suppl 1","key":"10.1016\/bs.acr.2026.02.007_bib0045","first-page":"S23","article-title":"Mda-7\/IL-24, a novel cancer selective apoptosis inducing cytokine gene: From the laboratory into the clinic","volume":"2","author":"Fisher","year":"2003","journal-title":"Cancer Biology \\& Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/jir.1985.5.11","article-title":"Effects of combined treatment with interferon and mezerein on melanogenesis and growth in human melanoma cells","volume":"5","author":"Fisher","year":"1985","journal-title":"J. Interferon Res."},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0047","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0048","doi-asserted-by":"crossref","first-page":"182-","DOI":"10.1007\/s44337-025-00328-3","article-title":"Exploring the potential of oncolytic viral vectors in targeted cancer therapy: Advances, challenges and future directions","volume":"2","author":"Ghosh","year":"2025","journal-title":"Discover Medicine"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1566523044577997","article-title":"Transductional and transcriptional targeting of adenovirus for clinical applications","volume":"4","author":"Glasgow","year":"2004","journal-title":"Current Gene Therapy"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.intimp.2004.01.015","article-title":"Cytokine and tumor cell apoptosis inducing activity of Mda-7\/IL-24","volume":"4","author":"Gopalkrishnan","year":"2004","journal-title":"International Immunopharmacology"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0051","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.pharmthera.2005.11.005","article-title":"Mda-7\/IL-24: Multifunctional cancer-specific apoptosis-inducing cytokine","volume":"111","author":"Gupta","year":"2006","journal-title":"Pharmacology and Therapeutics"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0052","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/14712598.2011.558838","article-title":"Oncolytic vaccinia virus for the treatment of cancer","volume":"11","author":"Guse","year":"2011","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.007_bib0053","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4161\/cbt.26110","article-title":"Combining histone deacetylase inhibitors with MDA-7\/IL-24 enhances killing of renal carcinoma cells","volume":"14","author":"Hamed","year":"2013","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0054","article-title":"Ultrasound-targeted microbubble destruction: Modulation in the tumor microenvironment and application in tumor immunotherapy","volume":"13","author":"Han","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.007_bib0056","first-page":"362","article-title":"Exploiting synergies between radiation and oncolytic viruses","volume":"10","author":"Harrington","year":"2008","journal-title":"Current Opinion Molecular Therapy"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0057","doi-asserted-by":"crossref","first-page":"84-","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0058","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nature Medicine"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.007_bib0059","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient derived xenograft models: An emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discovery"},{"issue":"25","key":"10.1016\/bs.acr.2026.02.007_bib0060","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1038\/sj.onc.1206567","article-title":"Gadd34 functional domains involved in growth suppression and apoptosis","volume":"22","author":"Hollander","year":"2003","journal-title":"Oncogene"},{"issue":"48","key":"10.1016\/bs.acr.2026.02.007_bib0061","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1038\/sj.onc.1204897","article-title":"Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (Mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties","volume":"20","author":"Huang","year":"2001","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0062","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1540397","article-title":"Shaping viral immunotherapy towards cancer-targeted immunological cell death","volume":"15","author":"Isaeva","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0064","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42299-4","article-title":"Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control","volume":"13","author":"Jabir","year":"2023","journal-title":"Scientific Reports"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006780","article-title":"Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer","volume":"11","author":"Jhawar","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0066","first-page":"1153","article-title":"IL24 and its receptors regulate growth and migration of pancreatic cancer cells and are potential biomarkers for IL24 molecular therapy","volume":"36","author":"Jia","year":"2016","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0067","first-page":"285","article-title":"Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells","volume":"1","author":"Jiang","year":"1993","journal-title":"Molecular Cellular Differentiation"},{"key":"10.1016\/bs.acr.2026.02.007_bib0068","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"12684","article-title":"RaSH, a rapid subtraction hybridization approach for identifying and cloning differentially expressed genes","volume":"97","author":"Jiang","year":"2000"},{"key":"10.1016\/bs.acr.2026.02.007_bib0069","first-page":"2477","article-title":"Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression","volume":"11","author":"Jiang","year":"1995","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.007_bib0070","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/cgt.2009.23","article-title":"CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma","volume":"16","author":"Kaliverova","year":"2009","journal-title":"Cancer Gene Therapy"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0071","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0072","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrc2545","article-title":"Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer","volume":"9","author":"Kirn","year":"2009","journal-title":"Nature Reviews Cancer"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101309","article-title":"Characterization of AAV vectors: A review of analytical techniques and critical quality attributes","volume":"32","author":"Kontogiannis","year":"2024","journal-title":"Molecular Therapy Methods & Clinical Development"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0074","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1359-6101(02)00012-6","article-title":"The family of IL-10-related cytokines and their receptors: Related, but to what extent?","volume":"13","author":"Kotenko","year":"2002","journal-title":"Cytokine and Growth Factor Reviews"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.007_bib0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011198","article-title":"Novel fusion superkine, IL-24S\/IL-15, enhances immunotherapy of brain cancer","volume":"13","author":"Kumar","year":"2025","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.acr.2026.02.007_bib0076","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/bs.acr.2023.01.001","article-title":"Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy","volume":"160","author":"Kumar","year":"2023","journal-title":"Advances in Cancer Research"},{"issue":"11","key":"10.1016\/bs.acr.2026.02.007_bib176","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.44457","article-title":"Cardiometabolic Effects of Omnivorous vs Vegan Diets in Identical Twins: A Randomized Clinical Trial","volume":"6","author":"Landry","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/bs.acr.2026.02.007_bib0077","first-page":"985","article-title":"mda-7\/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience","volume":"31","author":"Lebedeva","year":"2007","journal-title":"Intl. J. Oncol."},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0078","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymthe.2004.08.012","article-title":"Mda-7\/IL-24: Exploiting cancer\u2019s Achilles\u2019 heel","volume":"11","author":"Lebedeva","year":"2005","journal-title":"Molecular Therapy"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0079","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1158\/1535-7163.MCT-08-0245","article-title":"Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis","volume":"7","author":"Lebedeva","year":"2008","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2\u20133","key":"10.1016\/bs.acr.2026.02.007_bib0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0163-7258(01)00132-2","article-title":"Differentiation therapy of human cancer: Basic science and clinical applications","volume":"90","author":"Leszczyniecka","year":"2001","journal-title":"Pharmacology & Therapeutics"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0081","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0082","doi-asserted-by":"crossref","first-page":"156-","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: Basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduction and Targeted Therapy 2023 8:1"},{"key":"10.1016\/bs.acr.2026.02.007_bib0083","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cytogfr.2024.09.003","article-title":"Adeno-associated virus therapies: Pioneering solutions for human genetic diseases","volume":"80","author":"Liu","year":"2024","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0084","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41416-022-02076-y","article-title":"Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect","volume":"128","author":"Liu","year":"2022","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0085","doi-asserted-by":"crossref","first-page":"160-","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: Technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.007_bib0086","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1158\/0008-5472.CAN-20-2604","article-title":"Enhancing cancer immunotherapy by engineering T cells to express tumoricidal MDA-7\/IL-24","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0087","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/v15051153","article-title":"PTTG1 enhances oncolytic adenovirus 5 entry into pancreatic adenocarcinoma cells by increasing CXADR expression","volume":"15","author":"Long","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/bs.acr.2026.02.007_bib0088","doi-asserted-by":"crossref","unstructured":"Luo, J., Xia, Q., Zhang, R., Lv, C., Zhang, W., Wang, Y., Cui, Q., Liu, L. I., Cai, R., and Qian, C. 2008. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with Mda-7\/IL-24 gene. Clinical Cancer Research. 14 (8), 2450\u20132457. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4596.","DOI":"10.1158\/1078-0432.CCR-07-4596"},{"key":"10.1016\/bs.acr.2026.02.007_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"Journal of Controlled Release"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/cancers17030441","article-title":"Heterogeneity in cancer","volume":"17","author":"MacDonald","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0091","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41416-023-02344-5","article-title":"Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)","volume":"129","author":"Mahalingam","year":"2023","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.acr.2026.02.007_bib0092","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.acr.2024.06.003","article-title":"Precision medicine focus on the central nervous system: Non-invasive therapeutic agent delivery with focused ultrasound and microbubbles","volume":"164","author":"Mannangatti","year":"2024","journal-title":"Advances in Cancer Research"},{"issue":"23","key":"10.1016\/bs.acr.2026.02.007_bib0093","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.7150\/jca.26437","article-title":"Oncolytic adenovirus harboring interleukin-24 improves chemotherapy for advanced prostate cancer","volume":"9","author":"Mao","year":"2018","journal-title":"Journal of Cancer"},{"key":"10.1016\/bs.acr.2026.02.007_bib0094","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/B978-0-12-411638-2.00004-5","article-title":"Molecular-genetic imaging of cancer","volume":"124","author":"Minn","year":"2014","journal-title":"Advances in Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/ijms23010072","article-title":"Insights into the mechanisms of action of MDA-7\/IL-24: A ubiquitous cancer-suppressing protein","volume":"23","author":"Modi","year":"2021","journal-title":"International Journal Molecular Science"},{"key":"10.1016\/bs.acr.2026.02.007_bib0096","article-title":"Leveraging synthetic virology for the rapid engineering of vesicular stomatitis virus (VSV)","author":"Moles","year":"2024","journal-title":"BioRxiv"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0097","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nature Reviews Immunology"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0098","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical trials with oncolytic measles virus: Current status and future prospects","volume":"18","author":"Msaouel","year":"2017","journal-title":"Current Cancer Drug Targets"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0099","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cgt.2012.14","article-title":"Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-\u03b2","volume":"19","author":"Naik","year":"2012","journal-title":"Cancer Gene Therapy"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.007_bib0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"Biodrugs"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.007_bib0101","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma","volume":"24","author":"Noonan","year":"2016","journal-title":"Molecular Therapy"},{"issue":"July","key":"10.1016\/bs.acr.2026.02.007_bib0102","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2017.00153","article-title":"Combining oncolytic adenovirus with radiation\u2014a paradigm for the future of radiosensitization","volume":"7","author":"O\u2019Cathail","year":"2017","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618751","article-title":"Viral warfare: Unleashing engineered oncolytic viruses to outsmart cancer\u2019s defenses","volume":"16","author":"Omolekan","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0104","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.molonc.2015.04.009","article-title":"Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer","volume":"9","author":"Ottolino-Perry","year":"2015","journal-title":"Molecular Oncology"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0105","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2009.283","article-title":"Intelligent design: Combination therapy with oncolytic viruses","volume":"18","author":"Ottolino-Perry","year":"2009","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0106","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/mol.110.069484","article-title":"A serotype 5\/3 adenovirus expressing MDA-7\/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels","volume":"79","author":"Park","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/bs.acr.2026.02.007_bib0107","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1158\/1535-7163.MCT-09-0073","article-title":"MDA-7\/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide\/CD95\/PERK-dependent mechanism","volume":"8","author":"Park","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/bs.acr.2026.02.007_bib0108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4161\/auto.5725","article-title":"PERK-dependent regulation of MDA-7\/IL-24-induced autophagy in primary human glioma cells","volume":"4","author":"Park","year":"2008","journal-title":"Autophagy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0109","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.immunol.22.012703.104622","article-title":"Interleukin-10 and related cytokines and receptors","volume":"22","author":"Pestka","year":"2004","journal-title":"Annual Review of Immunology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0110","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.10","article-title":"Designing herpes viruses as oncolytics","volume":"2","author":"Peters","year":"2015","journal-title":"Molecular Therapy Oncolytics"},{"key":"10.1016\/bs.acr.2026.02.007_bib0111","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.812560","article-title":"Enhanced cancer therapy using an engineered designer cytokine alone and in combination with an immune checkpoint inhibitor","volume":"12","author":"Pradhan","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0112","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.18632\/oncotarget.27150","article-title":"Mechanism of internalization of MDA-7\/IL-24 protein and its cognate receptors following ligand-receptor docking","volume":"104","author":"Pradhan","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0113","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.21037\/jtd.2018.01.101","article-title":"The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy","volume":"10","author":"Qian","year":"2018","journal-title":"Journal of Thoracic Disease"},{"issue":"10","key":"10.1016\/bs.acr.2026.02.007_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140124","article-title":"Effects of adenovirus type 5 E1A isoforms on viral replication in arrested human cells","volume":"10","author":"Radko","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0116","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clinical and Experimental Medicine"},{"key":"10.1016\/bs.acr.2026.02.007_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116755","article-title":"PSMC2 promotes resistance against temozolomide in glioblastoma via suppressing JNK-mediated autophagic cell death","volume":"233","author":"Roy","year":"2025","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111809","article-title":"PSMC2 upregulation enhances epithelial-to-mesenchymal transition in glioblastoma via activating AKT\/GSK3\u03b2\/\u03b2-catenin axis","volume":"132","author":"Roy","year":"2025","journal-title":"Cellular Signalling"},{"key":"10.1016\/bs.acr.2026.02.007_bib0119","first-page":"213","article-title":"Measles virus for cancer therapy","volume":"330","author":"Russell","year":"2009","journal-title":"Current Topics in Microbiology and Immunology"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0120","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4110\/in.2012.12.1.1","article-title":"Molecular mechanisms governing IL-24 gene expression","volume":"12","author":"Sahoo","year":"2012","journal-title":"Immune Network"},{"key":"10.1016\/bs.acr.2026.02.007_bib0122","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1517\/14712598.7.5.577","article-title":"Melanoma differentiation associated gene-7 (mda-7)\/IL-24: A \u201cmagic bullet\u201d for cancer therapy?","volume":"7","author":"Sarkar","year":"2007","journal-title":"Expert Opinion Biological Therapy"},{"key":"10.1016\/bs.acr.2026.02.007_bib0123","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/0008-5472.CAN-07-0195","article-title":"Eradication of therapy resistant human prostate tumors using a cancer terminator virus","volume":"67","author":"Sarkar","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acr.2026.02.007_bib0124","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/cgt.2008.14","article-title":"A cancer terminator virus (CTV) eradicates both treated primary and untreated distant human melanomas","volume":"15","author":"Sarkar","year":"2008","journal-title":"Cancer Gene Therapy"},{"issue":"14","key":"10.1016\/bs.acr.2026.02.007_bib0125","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4161\/cc.5.14.3095","article-title":"Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Efficacious reagents for cancer gene therapy","volume":"5","author":"Sarkar","year":"2006","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"key":"10.1016\/bs.acr.2026.02.007_bib0126","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"10054","article-title":"Mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of P38 MAPK","volume":"99","author":"Sarkar","year":"2002"},{"key":"10.1016\/bs.acr.2026.02.007_bib0127","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"14034","article-title":"Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice","volume":"102","author":"Sarkar","year":"2005"},{"issue":"19","key":"10.1016\/bs.acr.2026.02.007_bib0128","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1158\/0008-5472.CAN-05-1261","article-title":"Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice","volume":"65","author":"Sarkar","year":"2005","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/1566524013666131118110827","article-title":"Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus","volume":"14","author":"Sarkar","year":"2014","journal-title":"Current Molecular Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20071641","article-title":"Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates","volume":"205","author":"Sarkar","year":"2008","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.1016\/bs.acr.2026.02.007_bib0131","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1078059","article-title":"Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic","volume":"5","author":"Sarkar","year":"2015","journal-title":"Oncoimmunology"},{"issue":"13","key":"10.1016\/bs.acr.2026.02.007_bib0132","doi-asserted-by":"crossref","first-page":"10712","DOI":"10.18632\/oncotarget.3544","article-title":"Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic","volume":"6","author":"Sarkar","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acr.2026.02.007_bib0133","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"9763","article-title":"Autocrine regulation of Mda-7\/IL-24 mediates cancer-specific apoptosis","volume":"105","author":"Sauane","year":"2008"},{"key":"10.1016\/bs.acr.2026.02.007_bib0134","doi-asserted-by":"crossref","first-page":"21669","DOI":"10.1074\/jbc.M116.737569","article-title":"Melanoma differentiation associated gene 7\/IL-24 exerts cytotoxic effects by altering the alternative splicing of Bcl-x pre-mRNA via he SRC\/PKC\u03b4 signaling axis","volume":"291","author":"Shapiro","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10555-025-10255-5","article-title":"Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings","volume":"44","author":"Sharma","year":"2025","journal-title":"Cancer Metastasis Reviews"},{"key":"10.1016\/bs.acr.2026.02.007_bib0136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","article-title":"Recent advances in oncolytic adenovirus therapies for cancer","volume":"21","author":"Shaw","year":"2016","journal-title":"Current Opinion in Virology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0137","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","article-title":"Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective","volume":"25","author":"Sherafat","year":"2025","journal-title":"Clinical and Experimental Medicine"},{"issue":"52","key":"10.1016\/bs.acr.2026.02.007_bib0138","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1038\/sj.onc.1209041","article-title":"Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer","volume":"24","author":"Shmulevitz","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/bs.acr.2026.02.007_bib0139","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic viruses and immune checkpoint inhibition: The best of both worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Molecular Therapy Oncolytics"},{"key":"10.1016\/bs.acr.2026.02.007_bib0140","first-page":"10","article-title":"Differentiation therapy of cancer: Journey from the laboratory into the clinic","volume":"1","author":"Staudt","year":"2007","journal-title":"Advances in Gene, Molecular, and Cell Therapy"},{"issue":"13","key":"10.1016\/bs.acr.2026.02.007_bib0141","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/sj.onc.1208420","article-title":"Potential molecular mechanism for rodent tumorigenesis: Mutational generation of progression elevated gene-3 (PEG-3)","volume":"24","author":"Su","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/bs.acr.2026.02.007_bib0142","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1038\/sj.onc.1209271","article-title":"Ionizing radiation enhances therapeutic activity of mda-7\/IL-24: Overcoming radiation- and mda-7\/IL-24-resistance in prostate cancer cells overexpressing the anti-apoptotic proteins bcl-xLor bcl-2","volume":"25","author":"Su","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/bs.acr.2026.02.007_bib0143","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"1059","article-title":"Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter","volume":"102","author":"Su","year":"2005"},{"key":"10.1016\/bs.acr.2026.02.007_bib0144","series-title":"Proceedings of the National Academy of Sciences of the United States of America","first-page":"9125","article-title":"Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene","volume":"94","author":"Su","year":"1997"},{"issue":"30","key":"10.1016\/bs.acr.2026.02.007_bib0145","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1038\/sj.onc.1203666","article-title":"Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells","volume":"19","author":"Su","year":"2000","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0146","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/nar\/29.8.1661","article-title":"PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-Ras and v-Raf oncogene transformed rat embryo cells","volume":"29","author":"Su","year":"2001","journal-title":"Nucleic Acids Research"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0147","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/0008-5472.CAN-24-1241","article-title":"Circulating tumor microenvironment in metastasis","volume":"85","author":"Tang","year":"2025","journal-title":"Cancer Research"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0148","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/pharmaceutics16080986","article-title":"MiRNA-mediated mechanisms in the generation of effective and safe oncolytic viruses","volume":"16","author":"Toropko","year":"2024","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0149","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1158\/1541-7786.MCR-19-0836","article-title":"Radiation attenuates prostate tumor antiviral responses to vesicular stomatitis virus containing IFN\u03b2, resulting in pronounced antitumor systemic immune responses","volume":"18","author":"Udayakumar","year":"2020","journal-title":"Molecular Cancer Research"},{"issue":"4","key":"10.1016\/bs.acr.2026.02.007_bib0150","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"issue":"16","key":"10.1016\/bs.acr.2026.02.007_bib0151","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.3390\/cancers15164042","article-title":"Efficacy of systemically administered retargeted oncolytic herpes simplex viruses-clearance and biodistribution in na\u00efve and HSV-preimmune mice","volume":"15","author":"Vannini","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/bs.acr.2026.02.007_bib0152","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3390\/pathogens12070896","article-title":"Exploring the molecular basis of vesicular stomatitis virus pathogenesis in swine: Insights from expression profiling of primary macrophages infected with M51R mutant virus","volume":"12","author":"Velazquez-Salinas","year":"2023","journal-title":"Pathogens"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0153","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4161\/cbt.2.5.440","article-title":"Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5\/3 chimerism","volume":"2","author":"Volk","year":"2003","journal-title":"Cancer Biology & Therapy"},{"issue":"2","key":"10.1016\/bs.acr.2026.02.007_bib0154","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic virotherapy: A new paradigm in cancer immunotherapy","volume":"25","author":"Volovat","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0156","doi-asserted-by":"crossref","first-page":"78-","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.007_bib0157","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1074\/jbc.M106043200","article-title":"Interleukin 24 (MDA-7\/MOB-5) signals through two heterodimeric receptors, IL-22R1\/IL-20R2 and IL-20R1\/IL-20R2","volume":"277","author":"Wang","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/bs.acr.2026.02.007_bib0158","first-page":"1","article-title":"Immunotherapy of cancer","volume":"128","author":"Wang","year":"2015","journal-title":"Advances in Cancer Research"},{"key":"10.1016\/bs.acr.2026.02.007_bib0159","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1517\/14656566.2011.629187","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4) as a novel therapeutic approach for advanced melanoma","volume":"12","author":"Wang","year":"2011","journal-title":"Expert Opinion Pharmacotherapy"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0160","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40164-025-00705-9","article-title":"Transforming cancer immunotherapy: Integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer","volume":"14","author":"Wang","year":"2025","journal-title":"Experimental Hematology & Oncology"},{"issue":"9","key":"10.1016\/bs.acr.2026.02.007_bib0161","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2174\/138920112800958850","article-title":"Bugs and drugs: Oncolytic virotherapy in combination with chemotherapy","volume":"13","author":"Wennier","year":"2012","journal-title":"Current Pharmaceutical Biotechnology"},{"issue":"12","key":"10.1016\/bs.acr.2026.02.007_bib0162","doi-asserted-by":"crossref","first-page":"9491","DOI":"10.1128\/JVI.72.12.9491-9502.1998","article-title":"Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins","volume":"72","author":"Wersto","year":"1998","journal-title":"Journal of Virology"},{"issue":"49","key":"10.1016\/bs.acr.2026.02.007_bib0163","doi-asserted-by":"crossref","first-page":"81208","DOI":"10.18632\/oncotarget.12820","article-title":"Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis","volume":"7","author":"Wilkinson","year":"2016","journal-title":"Oncotarget"},{"issue":"33","key":"10.1016\/bs.acr.2026.02.007_bib0164","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01346","article-title":"RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (IGNYTE)","volume":"43","author":"Wong","year":"2025","journal-title":"Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/bs.acr.2026.02.007_bib0165","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10162-022-00866-y","article-title":"Current advances in adeno-associated virus-mediated gene therapy to prevent acquired hearing loss","volume":"23","author":"Wu","year":"2022","journal-title":"JARO: Journal of the Association for Research in Otolaryngology"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.007_bib0166","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.virs.2025.11.002","article-title":"Oncolytic HSV-1 expressing GM-CSF and IL-12 enhances anti-tumor efficacy in immunocompetent murine melanoma model","volume":"40","author":"Xiao","year":"2025","journal-title":"Virologica Sinica"},{"key":"10.1016\/bs.acr.2026.02.007_bib0167","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","author":"Xu","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.acr.2026.02.007_bib0168","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OV.S145262","article-title":"Oncolytic virus delivery: From nano-pharmacodynamics to enhanced oncolytic effect","volume":"6","author":"Yokoda","year":"2017","journal-title":"Oncolytic Virotherapy"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0169","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"Journal Hematology Oncology"},{"issue":"20","key":"10.1016\/bs.acr.2026.02.007_bib0170","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1016\/j.cell.2025.08.033","article-title":"Epithelial-mesenchymal transition","volume":"188","author":"Zhang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/bs.acr.2026.02.007_bib0171","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.198911","article-title":"Recent advances in Reovirales viruses reverse genetics research","volume":"321","author":"Zhang","year":"2022","journal-title":"Virus Research"},{"issue":"8","key":"10.1016\/bs.acr.2026.02.007_bib0172","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/vaccines13080880","article-title":"Oncolytic herpes simplex virus therapy: Latest advances, core challenges, and future outlook","volume":"13","author":"Zheng","year":"2025","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0173","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01554-5","article-title":"Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening","volume":"17","author":"Zhong","year":"2024","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1016\/bs.acr.2026.02.007_bib0174","doi-asserted-by":"crossref","first-page":"5980","DOI":"10.1038\/s41467-022-33664-4","article-title":"Atomic model of vesicular stomatitis virus and mechanism of assembly","volume":"13","author":"Zhou","year":"2022","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/bs.acr.2026.02.007_bib0175","article-title":"The clinical advances of oncolytic viruses in cancer immunotherapy","volume":"15","author":"Zolaly","year":"2023","journal-title":"Cureus"}],"container-title":["Advances in Cancer Research","Viruses as Therapeutic Agents for Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065230X26000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:28:20Z","timestamp":1785904100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065230X26000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443432361"],"references-count":176,"URL":"https:\/\/doi.org\/10.1016\/bs.acr.2026.02.007","relation":{},"ISSN":["0065-230X"],"issn-type":[{"value":"0065-230X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}